Gilead Sciences, Inc (NASDAQ: GILD) is 16.92% higher on its value in year-to-date trading and has touched a low of $62.69 and a high of $119.96 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GILD stock was last observed hovering at around $110.83 in the last trading session, with the day’s loss setting it -2.83%.
Currently trading at $108.00, the stock is -1.51% and 2.07% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.6 million and changing -2.55% at the moment leaves the stock 10.84% off its SMA200. GILD registered 69.92% gain for a year compared to 6-month gain of 16.91%.
The stock witnessed a 5.37% loss in the last 1 month and extending the period to 3 months gives it a -2.02%, and is -1.90% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.35% over the week and 1.63% over the month.
Gilead Sciences, Inc (GILD) has around 17600 employees, a market worth around $134.34B and $28.69B in sales. Current P/E ratio is 22.71 and Fwd P/E is 12.67. Profit margin for the company is 20.79%. Distance from 52-week low is 72.29% and -9.97% from its 52-week high. The company has generated returns on investments over the last 12 months (14.44%).
The EPS is expected to grow by 72.27% this year.
Gilead Sciences, Inc (GILD) Top Institutional Holders
The shares outstanding are 1.25B, and float is at 1.24B with Short Float at 1.69%.
The top institutional shareholder in the company is BLACKROCK INC. with over 120.63 million shares valued at $8.28 billion. The investor’s holdings represent 9.6738% of the GILD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 115.26 million shares valued at $7.91 billion to account for 9.2431 of the shares outstanding. The other top investors are CAPITAL WORLD INVESTORS which holds 76.25 million shares representing 6.1147% and valued at over $5.23 billion, while CAPITAL RESEARCH GLOBAL INVESTORS holds 4.8458 of the shares totaling 60.43 million with a market value of $4.15 billion.
Gilead Sciences, Inc (GILD) Insider Activity
The most recent transaction is an insider sale by Dickinson Andrew D, the company’s Chief Financial Officer. SEC filings show that Dickinson Andrew D sold 2,500 shares of the company’s common stock on Jun 16 ’25 at a price of $110.17 per share for a total of $0.28 million. Following the sale, the insider now owns 0.17 million shares.
Gilead Sciences, Inc disclosed in a document filed with the SEC on Jun 16 ’25 that Mercier Johanna (Chief Commercial Officer) sold a total of 3,000 shares of the company’s common stock. The trade occurred on Jun 16 ’25 and was made at $110.17 per share for $0.33 million. Following the transaction, the insider now directly holds 0.12 million shares of the GILD stock.
Still, SEC filings show that on Jun 16 ’25, JOHANNA MERCIER (Officer) Proposed Sale 3,000 shares at an average price of $110.17 for $0.33 million. The insider now directly holds shares of Gilead Sciences, Inc (GILD).
